BACKGROUND: Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk. METHODS: Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations. RESULTS: Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk. CONCLUSIONS:High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk.
RCT Entities:
BACKGROUND: Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk. METHODS: Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations. RESULTS: Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk. CONCLUSIONS: High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk.
Authors: Alan R Kristal; Kathryn B Arnold; Jeannette M Schenk; Marian L Neuhouser; Noel Weiss; Phyllis Goodman; Colleen M Antvelink; David F Penson; Ian M Thompson Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal Journal: Prostate Date: 2008-09-15 Impact factor: 4.104
Authors: Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson Journal: Am J Epidemiol Date: 2008-10-21 Impact factor: 4.897
Authors: Alan R Kristal; Kathryn B Arnold; Jeannette M Schenk; Marian L Neuhouser; Phyllis Goodman; David F Penson; Ian M Thompson Journal: Am J Epidemiol Date: 2008-02-07 Impact factor: 4.897
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Jeannette M Schenk; Rachel Hunter-Merrill; Yingye Zheng; Ruth Etzioni; Roman Gulati; Catherine Tangen; Ian M Thompson; Alan R Kristal Journal: Am J Epidemiol Date: 2013-06-28 Impact factor: 4.897
Authors: D S Lopez; S B Peskoe; K K Tsilidis; J Hoffman-Bolton; K J Helzlsouer; W B Isaacs; M W Smith; E A Platz Journal: Prostate Cancer Prostatic Dis Date: 2014-09-16 Impact factor: 5.554